An early alert indicator and trend forecasting model for pandemic situations in Germany.
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer
Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced ovarian cancer, a large randomized